Literature DB >> 19910303

Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.

L Naumann, D Huscher, J Detert, M Spengler, G-R Burmester, F Buttgereit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19910303     DOI： 10.1136/ard.2009.111807

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.

Authors:  Vivian K Kawai; Carlos G Grijalva; Patrick G Arbogast; Jeffrey R Curtis; Daniel H Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F Mitchel; C Michael Stein; Marie R Griffin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-10       Impact factor: 4.794

Review 2.  Anti-inflammatory glucocorticoid drugs: reflections after 60 years.

Authors:  Michael W Whitehouse
Journal:  Inflammopharmacology       Date:  2010-10-31       Impact factor: 4.473

Review 3.  Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis.

Authors:  Jos N Hoes; Johannes W G Jacobs; Frank Buttgereit; Johannes W J Bijlsma
Journal:  Nat Rev Rheumatol       Date:  2010-12       Impact factor: 20.543

4.  Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation.

Authors:  L Dejager; K Dendoncker; M Eggermont; J Souffriau; F Van Hauwermeiren; M Willart; E Van Wonterghem; T Naessens; M Ballegeer; S Vandevyver; H Hammad; B Lambrecht; K De Bosscher; J Grooten; C Libert
Journal:  Mucosal Immunol       Date:  2015-03-11       Impact factor: 7.313

5.  Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Authors:  Rieke Alten; Hubert Nüßlein; Mauro Galeazzi; Hanns-Martin Lorenz; Michael T Nurmohamed; William G Bensen; Gerd R Burmester; Hans-Hartmut Peter; Karel Pavelka; Mélanie Chartier; Coralie Poncet; Christiane Rauch; Yedid Elbez; Manuela Le Bars
Journal:  RMD Open       Date:  2016-02-15

6.  Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry.

Authors:  Rachel J Black; Susan Lester; Rachelle Buchbinder; Claire Barrett; Marissa Lassere; Lyn March; Samuel Whittle; Catherine L Hill
Journal:  Arthritis Res Ther       Date:  2017-11-15       Impact factor: 5.156

7.  Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.

Authors:  R Westhovens; S E Connolly; J Margaux; M Vanden Berghe; M Maertens; M Van den Berghe; Y Elbez; M Chartier; F Baeke; S Robert; M Malaise
Journal:  Rheumatol Int       Date:  2020-06-17       Impact factor: 2.631

8.  Identification of Key Differentially Expressed Transcription Factors in Glioblastoma.

Authors:  Gang Qin; Beiquan Hu; Xianfeng Li; Rongjie Li; Youshi Meng; Yimei Wang; Donghua Zou; Feng Wei
Journal:  J Oncol       Date:  2020-06-15       Impact factor: 4.375

9.  Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study.

Authors:  Rachel J Black; Rebecca M Joseph; Benjamin Brown; Mohammad Movahedi; Mark Lunt; William G Dixon
Journal:  Arthritis Res Ther       Date:  2015-12-24       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.